Determinants of systemic availability of oral hydralazine in heart failure
Authors:
- 1 November 1985
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 38 (5) , 538-543
Abstract
Short-term therapy with oral hydralazine can favorably affect abnormal hemodynamics in patients with congestive heart failure, but the range of dosage is large. To investigate whether this variability in effective dose is a result of altered systemic availability, we studied 10 patients with congestive heart failure. Bioavailability (F) was calculated as the ratio of the blood AUC for a single 75 mg oral dose to the AUC of a 0.3 mg/kg iv dose. Acetylation capability was determined by sulfamethazine metabolic clearance (CLsmz). The F value in six subjects with CLsmz greater than 100 ml/min was 9.9% +/- 6.0% (means +/- SD) and was lower than the value of 26.2% +/- 13.0% (P less than 0.05) in the four patients with CLsmz less than 60 ml/min. Thus acetylation ability is an important consideration during low-dose hydralazine therapy (less than or equal to 225 mg/day). The clearance of the single intravenous dose of hydralazine averaged 29.5 +/- 8.0 ml/min/kg, which is not different than that reported in populations without heart failure. After oral dosage titration to induce maximum hemodynamic changes, the dose-normalized hydralazine AUC rose from 53.5 +/- 50.5 to 247.2 +/- 213.4 min/L X 10(3). Thus large oral doses of hydralazine result in disproportionate increases in systemic availability compatible with saturation of the first-pass effect or systemic clearance. In the doses required for maximum hemodynamic effects in our patients (225 to 3000 mg/day), this saturation phenomenon was a prominent determinant of systemic availability.Keywords
This publication has 9 references indexed in Scilit:
- Effect of intravenous dose on hydralazine kinetics after administrationClinical Pharmacology & Therapeutics, 1983
- Prazosin and Hydralazine in Congestive Heart FailureAnnals of Internal Medicine, 1981
- Hydralazine and isosorbide dinitrate: comparative central and regional hemodynamic effects when administered alone or in combination.Circulation, 1981
- Hydralazine kinetics after single and repeated oral dosesClinical Pharmacology & Therapeutics, 1980
- Hydralazine kinetics in hypertensive patients after intravenous administrationClinical Pharmacology & Therapeutics, 1980
- Importance of Left Ventricular Chamber Size in Determining the Response to Hydralazine in Severe Chronic Heart FailureNew England Journal of Medicine, 1980
- Renal effects of nitroprusside and hydralazine in patients with congestive heart failure.Circulation, 1980
- Dose‐dependent changes in sulfamethazine kinetics in rapid and slow isoniazid acetylatorsClinical Pharmacology & Therapeutics, 1978
- Studies on hydralazineEuropean Journal of Clinical Pharmacology, 1976